Leukaemia patients given hope by NHS drugs watchdog
But Nice is continuing to refuse to recommend that NHS managers fund two other alternative treatments for the disease. Mike Hobday, Head of Policy at Macmillan Cancer Support, said: “It is good news that Nice has approved nilotinib for cancer patients …
See all stories on this topic »